Math over Myth

Math Over Myth: September Psychedelic Stock News Roundup

Track the monthly performance of the psychedelic stock sector with our Math over Myth Stock News Roundup
Math over Myth

Math Over Myth: MindMed’s Self Destructive Stock Mission

Psychedelic stock MindMed enters free fall as news of a private equity offering of common stock spooks retail investors
Havn Life Collapses

Math Over Myth: Psychedelic Stock HAVN Life Collapses

The psychedelic corporate shakeout continues as another company, HAVN Life Sciences, folds due to lack of cash flow
Psychedelics in Palliative Care

End of Life: Psychedelics in Palliative Care

We interview Dr. Paul Thielking, Chief Science Officer of Numinus, about the use of psychedelics in palliative care and end of life care
Math over Myth MindMed

Math Over Myth: Spotlight on MindMed

In the latest installment of Math Over Myth we navigate psychedelic stock MindMed’s reverse split with Fibonacci numbers
Math over Myth ATAI Compass

Math Over Myth: Spotlight on Psychedelic Stocks ATAI & COMPASS

If you want to invest in psychedelic stocks, ignore the hype and look at the technicals. We take a deep dive on atai Life Sciences & COMPASS Pathways
ARK Invest psychedelic

Psychedelic Stocks: ARK Invest and the Reverse Midas Touch

, ,
Cathie Wood is buying up stocks from the most dubious actors in the psychedelic sector. Given ARK Invest’s subpar performance, is that a good thing?
Psychedelic Stocks

Psychedelic Stocks: MindMed and atai Slash their Pipelines, Mydecine Collapses

The psychedelic renaissance hits a rough patch as major companies look to tighten their belts or face total collapse. What’s happening with Psychedelic Stocks?
MindMed 18-MC Ibogaine Opioid Addiction

MindMed Shelves 18-MC for Opioid Use Disorder and Further Cuts Pipeline

MindMed drops its proprietary ibogaine for opioid addiction research amidst an ongoing shakeup. What is going on with this psychedelics company?